Respiratory Syncytial Virus Vaccine Market Forecast Analysis Through 2030 With Insights On Industry Expansion
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Respiratory Syncytial Virus Vaccine Market During The Forecast Period?
The respiratory syncytial virus vaccine market size has shown substantial growth in recent years. It is anticipated to expand from $1378.59 million in 2025 to $1482.18 million in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth can be linked to factors such as an increasing incidence of RSV-related hospitalizations, the unmet medical need for infant immunization, greater awareness of respiratory viral infections, public health surveillance of seasonal RSV outbreaks, and the expansion of clinical trial activity.
The respiratory syncytial virus vaccine market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $1957.68 million in 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. This projected rise during the forecast period can be primarily attributed to several factors, including the increasing approval of new RSV vaccines, augmented government funding for immunization initiatives, greater acceptance among older demographics, the broadening scope of preventive healthcare programs, and an intensified focus on creating combination vaccines. Significant trends expected within this period encompass the accelerated development of RSV vaccines targeting high-risk groups, a heightened emphasis on immunization programs for children and the elderly, increased investment in advanced vaccine formulations, the proliferation of hospital-led vaccination drives, and a stronger focus on sustained RSV prevention strategies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20195&type=smp
What Primary Factors Are Fueling The Expansion Of The Respiratory Syncytial Virus Vaccine Market?
The future expansion of the respiratory syncytial virus vaccine market is anticipated due to the increasing occurrence of respiratory infections. These infections refer to conditions resulting from viruses, bacteria, or other disease-causing agents, impacting parts of the respiratory system such as the sinuses, throat, airways, or lungs. Several elements contribute to this increase in respiratory infections, including air pollution, climate change, growing urbanization, demographic shifts towards older populations, and the appearance of drug-resistant pathogens. Specifically, the respiratory syncytial virus (RSV) vaccine plays a crucial role in lowering the rate of respiratory infections by preventing diseases linked to RSV, particularly among susceptible groups like infants and the elderly. An example illustrating this trend comes from October 2024, where data from the UK Health Security Agency, a UK-based government body, showed that tuberculosis (TB) cases in England surged by 10.7% year-over-year in 2023, escalating from 4,380 cases in 2022 to 4,850 cases. Consequently, the escalating frequency of respiratory infections is set to fuel the expansion of the respiratory syncytial virus vaccine market.
How Are Different Segment Groups Identified Within The Respiratory Syncytial Virus Vaccine Market?
The respiratory syncytial virus vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Clinical Indications: Pediatric Indication, Geriatric Indication, High-Risk Individuals
3) By Distribution Channel: Hospital And Others Pharmacies, Government Suppliers
Which Trends Are Affecting The Respiratory Syncytial Virus Vaccine Market Framework?
Major companies operating in the respiratory syncytial virus (RSV) vaccine market are concentrating on developing innovative solutions, including recombinant protein-based vaccine technologies. This effort addresses the growing demand for highly effective vaccines, improved immune protection, and safer formulations for older adults at elevated risk of RSV complications. Recombinant protein-based vaccines are developed using genetically engineered proteins that imitate viral components, which enables strong, targeted immune responses without the use of live viruses, offering a more controlled and stable alternative to conventional vaccine approaches. For instance, in May 2023, GlaxoSmithKline plc, a UK-based pharmaceutical company, obtained FDA approval for Arexvy. Arexvy is the first RSV vaccine specifically designed to prevent lower respiratory tract disease caused by RSV in individuals aged 60 and older. Arexvy utilizes advanced recombinant protein technology to target the RSV fusion (F) protein, a critical viral component essential for infection, thereby providing robust protection for older adults.
Who Are The Leading Firms Participating In The Respiratory Syncytial Virus Vaccine Market?
Major companies operating in the respiratory syncytial virus vaccine market are Pfizer Inc., GlaxoSmithKline plc, Moderna Inc.
Access The Complete Respiratory Syncytial Virus Vaccine Market Report:
Which Region Has The Strongest Presence In The Respiratory Syncytial Virus Vaccine Market?
North America was the largest region in the respiratory syncytial virus vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
